SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...

GSK's former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

to revize the terms on which Zhifei will commercialize GSK’s shingles vaccine, Shingrix,in mainland China. The revised agreement extends the original three-year period (2024-2026) during which Zhifei ...

GSK said on Thursday that Zhifei will commercialise its shingles vaccine, Shingrix, in mainland China, with the revised agreement extending the original three-year period during which the latter ...

Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...